Received Oct 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 5N9L9 | — |
Under age administration (this is the first dose of Diphtheria, Tetanus, and Pertussis series); Under age administration (this is the first dose of Diphtheria, Tetanus, and Pertussis series); This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 3-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 5N9L9, expiry date 28-NOV-2027) for prophylaxis. On 13-OCT-2025, the patient received the 1st dose of Boostrix. On 13-OCT-2025, an unknown time after receiving Boostrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Under age administration (this is the first dose of Diphtheria, Tetanus, and Pertussis series)) and underdose (Verbatim: Under age administration (this is the first dose of Diphtheria, Tetanus, and Pertussis series)). The outcome of the inappropriate age at vaccine administration and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 14-OCT-2025 Clinic Manager/Registered nurse called asking for advice about the underage administration of Boostrix on a three year old patient (this is the first dose of Diphtheria, Tetanus, and Pertussis series). Vaccination date, vaccine detail and patient demographics were obtained in this call.